
A look back at some of the biggest stories in 2023, from our US partners at Ophthalmology Times
A look back at some of the biggest stories in 2023, from our US partners at Ophthalmology Times
From FDA approvals to innovations in lens tech, 2023 was a big year in eye care
A review of our most important content from throughout the year
Real-world data from using faricimab to treat neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME)
The technology provides effective, efficient evaluations when paired with the right patients
In 2024, the waiting game will pay off for glaucoma specialists who are eager to develop fluency and implement new devices into their practices
Analysis suggested no evidence for a causal association of lifetime cannabis use and cannabis use disorder with primary open-angle glaucoma
The case for treating keratoconus without waiting for disease progression
Why “acceleration” is the industry keyword for 2024
EXN407 has the potential to be the first topical treatment for diabetic retinopathy and diabetic macular oedema
The study results will help to identify dosing levels for future clinical trials
Working smarter, not harder, to benefit patients
Orbis advances cataract surgery training in low-resource areas with technology
Experts from around the globe converged in San Francisco, California
Austrian investigators recommend an interdisciplinary, rheumatologic–ophthalmologic approach to disease management
Restoration and regeneration represent a new paradigm
A retrospective observational study shows BCVA was maintained after 6 months for patients with neovascular AMD
In recognition of global Geographic Atrophy Week, Prevent Blindness is providing free educational resources on GA for patients, care partners and healthcare professionals
At this year’s EURETINA meeting, retina specialists highlighted important developments in diabetic macular oedema and diabetic retinopathy research
Data show transfection in both eyes despite unilateral injection
In early November, the EU MDR issued a CE mark certification for RetInSight’s AI-based geographic atrophy monitor
The carbomer-containing eye gels carry risk of microbial contamination, the regulatory agency warned
Moving toward eliminating drug and chemical safety testing in animals
At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
Patients who received digital education demonstrated a better understanding of their disease and its management
At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials
Dr Marco Zarbin emphasises the importance of defining “active disease”
In the clinical trial, Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint
Infrastructure across Europe needs a major overhaul to optimise education and patient access in groundbreaking treatments